FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Bio­phar­ma’s res­i­dent an­ti­body-drug con­ju­gate ex­pert Seagen has scored a clutch of on­col­o­gy ap­provals in re­cent years, find­ing gold in what are known as “third-gen” AD­Cs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER